一种由个体患者报告的反应轨迹定义的溃疡性结肠炎分类法。
完整摘要 · 中文译文
溃疡性结肠炎(UC)精准医疗的一个障碍是无法预测和机制性地解释治疗反应。利用一项纳入768名参与者的3b期对照试验中的患者报告结局(PROs),我们识别出维多珠单抗(抗整合素)和阿达木单抗(抗肿瘤坏死因子)的四种不同的患者反应轨迹组。在另一项纳入576名参与者的3期试验中进行验证,将PRO定义的维多珠单抗轨迹与长期疾病并发症相关联。批量、单细胞和空间转录组学及蛋白质组学鉴定出血管炎症通过SPP1+巨噬细胞与内皮细胞之间的相互作用与维多珠单抗无反应相关。在两个分别纳入4,981名和3,854名UC患者的独立真实世界队列中,合并使用肾素-血管紧张素系统抑制剂(血管炎症调节剂)与维多珠单抗长期并发症减少相关,但与抗细胞因子治疗无关。这些发现定义了一种基于反应轨迹的分类体系,其临床实用性需要前瞻性验证,并可用于在UC中选择维多珠单抗联合治疗。
完整摘要 · 英文原文
A barrier to precision medicine for ulcerative colitis (UC) is the inability to predict and mechanistically explain treatment responses. Using patient-reported outcomes (PROs) from a phase 3b comparative trial of 768 participants, we identified four distinct patient response-trajectory groups for vedolizumab (anti-integrin) and adalimumab (antitumor necrosis factor). Validation in a second phase 3 trial of 576 participants linked PRO-defined vedolizumab trajectories to long-term disease complications. Bulk, single cell, and spatial transcriptomics and proteomics identified vascular inflammation as associated with vedolizumab nonresponse through interactions between SPP1+ macrophages and endothelial cells. In two separate real-world cohorts of 4,981 and 3,854 patients with UC, concomitant use of renin-angiotensin system inhibitors (modulators of vascular inflammation) was associated with reduced long-term complications for vedolizumab but not anticytokine therapies. These findings define a response-trajectory-based taxonomy that requires prospective validation for clinical utility and applications for selecting vedolizumab combination therapy in UC.